Supplementary Tables S1-S4, Figures S1-S6,Supplementary Methods, and Supplementary Figure Legend from A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer